Evidence map›Paper›PMID 32104190›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2020

System Prediction and Validation of TCM for Chronic Myeloid Leukemia Treatment from the Perspective of Low-Toxicity Chemotherapy: A Stilbene

Bing-Yang Chai, Fu-Kai Gong, Ze-Hui Chen, Zhao-Xue Li, Bo Zhang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bing-Yang ChaiKey Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Shihezi University, Shihezi 832002, Xinjiang, China.
Fu-Kai GongKey Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Shihezi University, Shihezi 832002, Xinjiang, China.
Ze-Hui ChenKey Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Shihezi University, Shihezi 832002, Xinjiang, China.
Zhao-Xue LiKey Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Shihezi University, Shihezi 832002, Xinjiang, China.
Bo ZhangKey Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Shihezi University, Shihezi 832002, Xinjiang, China.ORCID https://orcid.org/0000-0003-3033-299X
Shihezi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn traditional Chinese medicine (TCM), chronic myeloid leukemia (CML) has been attributed to "poisoned bone marrow," which is viewed as a loss of Qi or blood, a deficiency in Yin or Yang that causes a complex imbalance between cell growth and death. Malignant myeloid progenitor cells display excessive growth that is difficult to control without toxicity. More than 60 herbs in TCM have shown efficacy against CML. However, the key molecules and mechanisms involved in the holistic-level characterization, as well as the effective target associations, are still unknown.

methodsThe present study employed a computational approach with filtering potential compounds via admetSAR, systems biology-based functional data prediction, and biochemical and molecular biological validation.

resultsWe generated 118 bioactive compounds from 11 herbs within four dialectical therapy groups that are most commonly used to treat CML and predicted 141 potential targets. The stilbene resveratrol and its derivatives were found to be highly related to these targets. Among them,

conclusionsOur work sheds light on the mechanism of the efficacy of the stilbene

Identifiers

PMID32104190
PMCPMC7035520
OpenAlexW3004613861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.